Mirum (MIRM) | Financial Analysis & Statements
Mirum Pharmaceuticals Inc. Mid-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
148.9M
Gross Profit
120.7M
81.02%
Operating Income
-4.6M
-3.07%
Net Income
-5.7M
-3.85%
EPS (Diluted)
$-0.11
Balance Sheet Metrics
Total Assets
842.8M
Total Liabilities
528.1M
Shareholders Equity
314.7M
Debt to Equity
1.68
Cash Flow Metrics
Operating Cash Flow
-116.0K
Free Cash Flow
5.5M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Mirum Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 521.3M | 336.9M | 186.4M | 77.1M | 19.1M |
| Cost of Goods Sold | 100.2M | 81.6M | 47.0M | 12.4M | 1.9M |
| Gross Profit | 421.1M | 255.2M | 139.3M | 64.7M | 17.2M |
| Gross Margin % | 80.8% | 75.8% | 74.8% | 83.9% | 90.1% |
| Operating Expenses | |||||
| Research & Development | 186.2M | 140.6M | 102.6M | 106.8M | 131.4M |
| Selling, General & Administrative | 257.0M | 202.2M | 145.9M | 89.1M | 59.2M |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 443.2M | 342.9M | 248.5M | 195.9M | 190.6M |
| Operating Income | -22.1M | -87.6M | -109.2M | -131.2M | -173.4M |
| Operating Margin % | -4.2% | -26.0% | -58.6% | -170.3% | -906.1% |
| Non-Operating Items | |||||
| Interest Income | 12.7M | 13.8M | 13.7M | 3.9M | 366.0K |
| Interest Expense | 14.4M | 14.3M | 15.1M | 16.0M | 17.6M |
| Other Non-Operating Income | 2.4M | 1.2M | -51.9M | 1.3M | 106.7M |
| Pre-tax Income | -21.4M | -86.9M | -162.4M | -142.1M | -84.0M |
| Income Tax | 1.9M | 1.0M | 991.0K | -6.4M | 37.0K |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Income | -23.4M | -87.9M | -163.4M | -135.7M | -84.0M |
| Net Margin % | -4.5% | -26.1% | -87.7% | -176.0% | -438.9% |
| Key Metrics | |||||
| EBITDA | 17.2M | -49.0M | -87.4M | -123.8M | -65.0M |
| EPS (Basic) | $-0.47 | $-1.85 | $-4.00 | $-4.01 | $-2.77 |
| EPS (Diluted) | $-0.47 | $-1.85 | $-4.00 | $-4.02 | $-2.77 |
| Basic Shares Outstanding | 50198304 | 47522594 | 40885124 | 33839072 | 30321722 |
| Diluted Shares Outstanding | 50198304 | 47522594 | 40885124 | 33839072 | 30321722 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Mirum Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 296.7M | 222.5M | 286.3M | 28.0M | 31.3M |
| Short-term Investments | 86.6M | 57.8M | 0 | 123.7M | 125.2M |
| Accounts Receivable | 123.3M | 78.3M | 68.0M | 24.0M | 3.3M |
| Inventory | 24.9M | 22.4M | 22.3M | 5.6M | 1.5M |
| Other Current Assets | 18.1M | 11.8M | 10.9M | 8.9M | 5.3M |
| Total Current Assets | 549.7M | 392.8M | 387.5M | 190.2M | 166.6M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 10.6M | 9.8M | 706.0K | 914.0K | 981.0K |
| Goodwill | 260.9M | 249.8M | 252.9M | 59.0M | 18.7M |
| Intangible Assets | 260.9M | 249.8M | 252.9M | 59.0M | 18.7M |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 13.5M | 5.8M | 4.2M | 101.4M | 101.8M |
| Total Non-Current Assets | 293.1M | 278.0M | 259.1M | 162.7M | 128.1M |
| Total Assets | 842.8M | 670.8M | 646.6M | 352.9M | 294.7M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 9.6M | 14.6M | 7.4M | 8.7M | 9.2M |
| Short-term Debt | 2.1M | 1.7M | 1.1M | 931.0K | 711.0K |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | - | - | - | 1.1M | 2.0M |
| Total Current Liabilities | 205.8M | 126.6M | 87.1M | 64.7M | 42.6M |
| Non-Current Liabilities | |||||
| Long-term Debt | 317.3M | 316.1M | 307.0M | 1.3M | 1.9M |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | 5.0M | 2.5M | 3.8M | 4.5M | 17.0K |
| Total Non-Current Liabilities | 322.3M | 318.6M | 310.9M | 146.1M | 131.8M |
| Total Liabilities | 528.1M | 445.1M | 398.0M | 210.9M | 174.4M |
| Equity | |||||
| Common Stock | 5.0K | 5.0K | 5.0K | 4.0K | 3.0K |
| Retained Earnings | -667.5M | -644.2M | -556.2M | -392.8M | -257.2M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 314.7M | 225.6M | 248.7M | 142.0M | 120.2M |
| Key Metrics | |||||
| Total Debt | 319.5M | 317.8M | 308.1M | 2.2M | 2.6M |
| Working Capital | 343.9M | 266.2M | 300.5M | 125.5M | 124.0M |
Balance Sheet Composition
Mirum Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -23.4M | -87.9M | -163.4M | -135.7M | -84.0M |
| Depreciation & Amortization | 24.2M | 23.6M | 10.8M | 3.2M | 595.0K |
| Stock-Based Compensation | 71.4M | 48.4M | 35.0M | 27.0M | 23.1M |
| Working Capital Changes | -14.0M | 23.4M | -19.0M | -17.4M | 21.0M |
| Operating Cash Flow | 60.4M | 9.8M | -80.1M | -113.9M | -129.3M |
| Investing Activities | |||||
| Capital Expenditures | -954.0K | -993.0K | -109.0K | -278.0K | -24.0K |
| Acquisitions | 0 | 0 | -212.8M | 0 | 0 |
| Investment Purchases | -97.4M | -89.0M | -27.3M | -132.3M | -198.0M |
| Investment Sales | 74.4M | 19.9M | 153.0M | 140.3M | 157.6M |
| Investing Cash Flow | -24.0M | -70.1M | -87.2M | 7.7M | 67.5M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | - | - | - | 0 |
| Debt Issuance | 0 | 0 | 305.3M | 0 | 0 |
| Debt Repayment | - | - | - | - | - |
| Financing Cash Flow | 0 | 0 | 326.1M | 101.8M | 71.4M |
| Free Cash Flow | 54.9M | -10.7M | -91.1M | -120.4M | -151.8M |
| Net Change in Cash | 36.5M | -60.3M | 158.9M | -4.3M | 9.6M |
Cash Flow Trend
Mirum Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-195.68
Forward P/E
-859.63
Price to Book
15.39
Price to Sales
10.80
PEG Ratio
2.52
Profitability Ratios
Profit Margin
-4.48%
Operating Margin
-3.07%
Return on Equity
-8.65%
Return on Assets
-1.83%
Financial Health
Current Ratio
2.67
Debt to Equity
101.51
Beta
0.52
Per Share Data
EPS (TTM)
$-0.47
Book Value per Share
$6.06
Revenue per Share
$10.39
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| MIRM | 5.5B | -195.68 | 15.39 | -8.65% | -4.48% | 101.51 |
| Vertex | 109.4B | 28.40 | 5.92 | 22.54% | 32.94% | 10.91 |
| Regeneron | 81.0B | 18.00 | 2.45 | 14.86% | 31.41% | 9.51 |
| Axsome Therapeutics | 9.5B | -50.54 | 105.31 | -252.12% | -28.69% | 247.03 |
| Praxis Precision | 9.6B | - | 9.46 | -45.83% | 0.00% | 0.01 |
| Bio-Techne | 9.1B | 117.16 | 4.55 | 3.80% | 6.41% | 20.07 |
Financial data is updated regularly. All figures are in the company's reporting currency.






